ABILIFY (Page 5 of 24)

Pediatric Patients and Adolescents

In an analysis of two placebo-controlled trials in adolescents with schizophrenia (13 to 17 years) and pediatric patients with bipolar disorder (10 to 17 years), the mean change in fasting glucose in ABILIFY-treated patients (+4.8 mg/dL; with a median exposure of 43 days; N=259) was not significantly different than in placebo-treated patients (+1.7 mg/dL; with a median exposure of 42 days; N=123).

In an analysis of two placebo-controlled trials in pediatric and adolescent patients with irritability associated with autistic disorder (6 to 17 years) with median exposure of 56 days, the mean change in fasting glucose in ABILIFY-treated patients (–0.2 mg/dL; N=83) was not significantly different than in placebo-treated patients (–0.6 mg/dL; N=33).

In an analysis of two placebo-controlled trials in pediatric and adolescent patients with Tourette’s disorder (6 to 18 years) with median exposure of 57 days, the mean change in fasting glucose in ABILIFY-treated patients (0.79 mg/dL; N=90) was not significantly different than in placebo-treated patients (–1.66 mg/dL; N=58).

Table 8 shows the proportion of patients with changes in fasting glucose levels from the pooled adolescent schizophrenia and pediatric bipolar patients (median exposure of 42-43 days), from two placebo-controlled trials in pediatric patients (6 to 17 years) with irritability associated with autistic disorder (median exposure of 56 days), and from the two placebo-controlled trials in pediatric patients (6 to 18 year) with Tourette’s Disorder (median exposure 57 days).

Table 8:Changes in Fasting Glucose From Placebo-Controlled Trials in Pediatric and Adolescent Patients
Category Change (at least once) from Baseline
Indication
Treatment Arm
n/N
%

Fasting Glucose

Normal to High

(<100 mg/dL to ≥126 mg/dL)

Pooled Schizophrenia and Bipolar Disorder
ABILIFY
2/236
0.8
Placebo
2/110
1.8
Irritability Associated with Autistic Disorder
ABILIFY
0/73
0
Placebo
0/32
0
Tourette’s Disorder
ABILIFY
3/88
3.4
1/58
1.7

Fasting Glucose

Borderline to High

(≥100 mg/dL and <126 mg/dL to ≥126 mg/dL)

Pooled Schizophrenia and Bipolar Disorder
ABILIFY
1/22
4.5
Placebo
0/12
0
Irritability Associated with Autistic Disorder
ABILIFY
0/9
0
Placebo
0/1
0
Tourette’s Disorder
ABILIFY
0/11
0
Placebo
0/4
0

At 12 weeks in the pooled adolescent schizophrenia and pediatric bipolar disorder trials, the mean change in fasting glucose in ABILIFY-treated patients was not significantly different than in placebo-treated patients [+2.4 mg/dL (n=81) and +0.1 mg/dL (n=15), respectively].

Dyslipidemia

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

There were no significant differences between ABILIFY- and placebo-treated patients in the proportion with changes from normal to clinically significant levels for fasting/nonfasting total cholesterol, fasting triglycerides, fasting LDLs, and fasting/nonfasting HDLs. Analyses of patients with at least 12 or 24 weeks of exposure were limited by small numbers of patients.

Adults

Table 9 shows the proportion of adult patients, primarily from pooled schizophrenia and bipolar disorder monotherapy placebo-controlled trials, with changes in total cholesterol (pooled from 17 trials; median exposure 21 to 25 days), fasting triglycerides (pooled from eight trials; median exposure 42 days), fasting LDL cholesterol (pooled from eight trials; median exposure 39 to 45 days, except for placebo-treated patients with baseline normal fasting LDL measurements, who had median treatment exposure of 24 days) and HDL cholesterol (pooled from nine trials; median exposure 40 to 42 days).

Table 9: Changes in Blood Lipid Parameters From Placebo-Controlled Monotherapy Trials in Adults
Treatment Arm
n/N
%

Total Cholesterol

Normal to High

(<200 mg/dL to ≥240 mg/dL)

ABILIFY
34/1357
2.5
Placebo
27/973
2.8

Fasting Triglycerides

Normal to High

(<150 mg/dL to ≥200 mg/dL)

ABILIFY
40/539
7.4
Placebo
30/431
7.0

Fasting LDL Cholesterol

Normal to High

(<100 mg/dL to ≥160 mg/dL)

ABILIFY
2/332
0.6
Placebo
2/268
0.7

HDL Cholesterol

Normal to Low

(≥40 mg/dL to <40 mg/dL)

ABILIFY
121/1066
11.4
Placebo
99/794
12.5

In monotherapy trials in adults, the proportion of patients at 12 weeks and 24 weeks with changes from Normal to High in total cholesterol (fasting/nonfasting), fasting triglycerides, and fasting LDL cholesterol were similar between ABILIFY- and placebo-treated patients: at 12 weeks, Total Cholesterol (fasting/nonfasting), 1/71 (1.4%) vs. 3/74 (4.1%); Fasting Triglycerides, 8/62 (12.9%) vs. 5/37 (13.5%); Fasting LDL Cholesterol, 0/34 (0%) vs. 1/25 (4.0%), respectively; and at 24 weeks, Total Cholesterol (fasting/nonfasting), 1/42 (2.4%) vs. 3/37 (8.1%); Fasting Triglycerides, 5/34 (14.7%) vs. 5/20 (25%); Fasting LDL Cholesterol, 0/22 (0%) vs. 1/18 (5.6%), respectively.

Table 10 shows the proportion of patients with changes in total cholesterol (fasting/nonfasting), fasting triglycerides, fasting LDL cholesterol, and HDL cholesterol from two placebo-controlled adjunctive trials in adult patients with major depressive disorder (median exposure 42 days).

Table 10: Changes in Blood Lipid Parameters From Placebo-Controlled Adjunctive Trials in Adult Patients with Major Depressive Disorder
Treatment Arm
n/N
%

Total Cholesterol

Normal to High

(<200 mg/dL to ≥240 mg/dL)

ABILIFY
3/139
2.2
Placebo
7/135
5.2

Fasting Triglycerides

Normal to High

(<150 mg/dL to ≥200 mg/dL)

ABILIFY
14/145
9.7
Placebo
6/147
4.1

Fasting LDL Cholesterol

Normal to High

(<100 mg/dL to ≥160 mg/dL)

ABILIFY
0/54
0
Placebo
0/73
0

HDL Cholesterol

Normal to Low

(≥40 mg/dL to <40 mg/dL)

ABILIFY
17/318
5.3
Placebo
10/286
3.5

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.